Chemical Engineering Commons^™

Haemophilic Factors Produced By Transgenic Livestock: Abundance That Can Enable Alternative Therapies Worldwide, Kevin E. Van Cott, Paul E. Monahan, Timothy C. Nichols, William H. Velander

Papers in Biotechnology

Haemophilia replacement factors, both plasma-derived and recombinant, are in relatively short supply and are high-cost products. This has stymied the study and development of alternative methods of administration of haemophilia therapy even in the most economically advanced countries, owing to the large amounts of material needed because bioabsorption and bioavailability of haemophilic factors can be less than 10% when using non-intravenous routes of delivery. There is therefore a need to increase access to therapy worldwide by decreasing the cost and increasing the abundance so that therapy can be achieved through simplified, alternative delivery methods. Transgenic livestock have been used to …